No Data
No Data
Rapid Dose Announces Closing of First Tranche of Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - July 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a first tranche of its previously
Rapid Dose Therapeutics Announces Payment in Shares for Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "No
Rapid Dose Therapeutics Reports Fiscal Year 2024 Financial Results
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), is pleased to announce the filing of its financial results for the year ended
Rapid Dose Therapeutics Vaccine Delivery Study Receives Mitacs Accelerate Grant
Burlington, Ontario--(Newsfile Corp. - June 25, 2024) - Rapid Dose Therapeutics Corp. ("RDT" or the "Company") trading on the Canadian Securities Exchange ("CSE") under the symbol DOSE is pleased to a
Rapid Dose Provides Update on Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - June 19, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that further to its press release dated May 8, 2024, regardin
Rapid Dose Therapeutics Commits to NFL-Funded Clinical Trial Application
Burlington, Ontario--(Newsfile Corp. - May 29, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces its collaboration in the National Football League (NFL) – funded cli